These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18935928)

  • 1. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?
    Almhanna K; Kim R
    Oncology (Williston Park); 2008 Sep; 22(10):1176-83; discussion 1190, 1192, 1196. PubMed ID: 18935928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line treatment for metastatic pancreatic cancer.
    Paluri RK; Kasi A; Young C; Posey JA
    Clin Adv Hematol Oncol; 2020 Feb; 18(2):106-115. PubMed ID: 32558804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
    Boeck S; Heinemann V
    Future Oncol; 2008 Feb; 4(1):41-50. PubMed ID: 18240999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
    Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
    Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional chemotherapy of advanced pancreatic cancer.
    Giuliani F; Di Maio M; Colucci G; Perrone F
    Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.
    Custodio A; Puente J; Sastre J; Díaz-Rubio E
    Cancer Treat Rev; 2009 Dec; 35(8):676-84. PubMed ID: 19758760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine in the treatment of metastatic pancreatic cancer.
    Hilbig A; Oettle H
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):511-23. PubMed ID: 18402518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
    Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
    Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
    Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
    Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
    Petrelli F; Borgonovo K; Ghilardi M; Cabiddu M; Barni S
    Rev Recent Clin Trials; 2010 Jan; 5(1):43-56. PubMed ID: 20205687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
    Kourie HR; Gharios J; Kattan J
    Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
    [No Abstract]   [Full Text] [Related]  

  • 18. Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer.
    Arshad A; Al-Leswas D; Al-Taan O; Stephenson J; Metcalfe M; Steward WP; Dennison AR
    Am J Clin Oncol; 2013 Aug; 36(4):411-4. PubMed ID: 21436672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in the treatment of cancer of the pancreas.
    Glimelius B
    J Hepatobiliary Pancreat Surg; 1998; 5(3):235-41. PubMed ID: 9880769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Boeck S; Heinemann V
    J Clin Oncol; 2008 Mar; 26(7):1178-9; author reply 1179. PubMed ID: 18309957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.